Company Filing History:
1 out of 60 
1 out of 4 
1 out of 56 Years Active: 2022
Title: Shingo Dan: Innovator in Cancer Treatment
Introduction
Shingo Dan is a prominent inventor based in Tokyo, Japan. He is recognized for his significant contributions to the field of cancer treatment, particularly through his innovative research on tyrosine kinase inhibitors.
Latest Patents
Shingo Dan holds a patent for a fourth-generation EGFR tyrosine kinase inhibitor. This compound exhibits specific inhibitory activity against the C797S resistant mutant EGFR, which is particularly relevant for treating non-small cell lung cancer that has developed resistance due to this mutation. His work provides a promising avenue for developing targeted therapies for patients facing this challenging condition.
Career Highlights
Throughout his career, Shingo Dan has worked with esteemed institutions such as Nagasaki University and Iwate Medical University. His research has focused on advancing the understanding and treatment of cancer, making him a valuable asset in the medical research community.
Collaborations
Shingo Dan has collaborated with notable colleagues, including Masatomo Iwao and Tsutomu Fukuda. These partnerships have contributed to the advancement of his research and the development of innovative solutions in cancer treatment.
Conclusion
Shingo Dan's work in developing a specific tyrosine kinase inhibitor showcases his dedication to improving cancer therapies. His contributions are vital in the ongoing fight against cancer, particularly for patients with resistant mutations.